source
- ADC Therapeutics shares plunge as Phase 3 trial of Zynlonta shows high death rate despite efficacy gainADC Therapeutics reported Phase 3 data for Zynlonta combined with rituximab in a hard-to-treat blood cancer. The trial met its primary endpoint by extending progression-free survival versus standar…
- Alnylam partners with Inceptive Nucleics on AI deal that could reach $2 billionAlnylam Pharmaceuticals announced a partnership with Inceptive Nucleics to apply artificial‑intelligence tools to its RNA‑based drug discovery program. The agreement provides an upfront $30 millio…